Disc Medicine surges after Phase 3 bitopertin trial clears all key endpoints

Disc Medicine (IRON) is up 35.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears tied to Disc Medicine’s October 19, 2026 announcement that bitopertin succeeded in the pivotal Phase 3 APOLLO study in erythropoietic protoporphyria. Investors likely viewed the all-endpoint win as a major regulatory and commercial positive because the program had previously received a Complete Response Letter, and management now plans to resubmit the application by the end of 2026.

Details:

Disc Medicine said bitopertin met both co-primary endpoints in APOLLO, including lowering whole-blood metal-free protoporphyrin IX and increasing time in light without pain.

The company also reported statistically significant results across all secondary endpoints, including fewer phototoxic reactions and better light tolerance, plus quality-of-life improvements.

Management said bitopertin was generally well tolerated in the trial, with no new safety signals observed and no treatment-emergent adverse events above Grade 3.

This update is especially important because the FDA issued a Complete Response Letter in February 2026; Disc later said a successful APOLLO trial could support a resubmission and potentially traditional approval.

Sources:

Disc Medicine, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IRON Insider Trading Activity

$IRON insiders have traded $IRON stock on the open market 39 times in the past 6 months. Of those trades, 0 have been purchases and 39 have been sales.

Here’s a breakdown of recent trading of $IRON stock by insiders over the last 6 months:

JOHN D QUISEL (Chief Executive Officer) has made 0 purchases and 9 sales selling 100,000 shares for an estimated $7,473,057.
KEVIN BITTERMAN has made 0 purchases and 16 sales selling 83,321 shares for an estimated $6,405,501.
JONATHAN YEN-WEN YU (Chief Operating Officer) has made 0 purchases and 8 sales selling 38,612 shares for an estimated $2,844,892.
RAHUL KHARA (Chief Legal Officer) has made 0 purchases and 6 sales selling 15,000 shares for an estimated $1,114,160.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive IRON Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$IRON Hedge Fund Activity

We have seen 104 institutional investors add shares of $IRON stock to their portfolio, and 86 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 1,875,795 shares (+inf%) to their portfolio in Q2 2026, for an estimated $137,195,646
VESTAL POINT CAPITAL, LP added 850,000 shares (+121.4%) to their portfolio in Q2 2026, for an estimated $62,169,000
ASSENAGON ASSET MANAGEMENT S.A. added 735,300 shares (+191.4%) to their portfolio in Q3 2026, for an estimated $48,132,737
ORBIMED ADVISORS LLC removed 710,015 shares (-66.5%) from their portfolio in Q2 2026, for an estimated $51,930,497
FMR LLC removed 692,421 shares (-12.4%) from their portfolio in Q2 2026, for an estimated $50,643,671
GOLDMAN SACHS GROUP INC removed 542,459 shares (-84.8%) from their portfolio in Q2 2026, for an estimated $39,675,451
OPALEYE MANAGEMENT INC. added 434,000 shares (+103.1%) to their portfolio in Q2 2026, for an estimated $31,742,760

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$IRON Price Targets

Multiple analysts have issued price targets for $IRON recently. We have seen 2 analysts offer price targets for $IRON in the last 6 months, with a median target of $86.5.

Here are some recent targets:

Sean Laaman from Morgan Stanley set a target price of $85.0 on 06/16/2026
David Nierengarten from Wedbush set a target price of $88.0 on 06/10/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.